These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 37523051)

  • 1. PK/PD and Bioanalytical Considerations of AAV-Based Gene Therapies: an IQ Consortium Industry Position Paper.
    Kavita U; Sun K; Braun M; Lembke W; Mody H; Kamerud J; Yang TY; Braun IV; Fang X; Gao W; Gupta S; Hofer M; Liao MZ; Loo L; McBlane F; Menochet K; Stubenrauch KG; Upreti VV; Vigil A; Wiethoff CM; Xia CQ; Zhu X; Jawa V; Chemuturi N
    AAPS J; 2023 Jul; 25(5):78. PubMed ID: 37523051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacology Considerations on Recombinant Adeno-Associated Virus-Based Gene Therapy.
    Sun K; Liao MZ
    J Clin Pharmacol; 2022 Dec; 62 Suppl 2():S79-S94. PubMed ID: 36461742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for Method Development and Validation of qPCR and dPCR Assays in Support of Cell and Gene Therapy Drug Development.
    Hays A; Wissel M; Colletti K; Soon R; Azadeh M; Smith J; Doddareddy R; Chalfant M; Adamowicz W; Ramaswamy SS; Dholakiya SL; Guelman S; Gullick B; Durham J; Rennier K; Nagilla P; Muruganandham A; Diaz M; Tierney C; John K; Valentine J; Lockman T; Liu HY; Moritz B; Ouedraogo JP; Piche MS; Smet M; Murphy J; Koenig K; Zybura A; Vyhlidal C; Mercier J; Jani N; Kubista M; Birch D; Morse K; Johansson O
    AAPS J; 2024 Feb; 26(1):24. PubMed ID: 38316745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-Body Disposition and Physiologically Based Pharmacokinetic Modeling of Adeno-Associated Viruses and the Transgene Product.
    Liu S; Chowdhury EA; Xu V; Jerez A; Mahmood L; Ly BQ; Le HK; Nguyen A; Rajwade A; Meno-Tetang G; Shah DK
    J Pharm Sci; 2024 Jan; 113(1):141-157. PubMed ID: 37805073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper.
    Yang TY; Braun M; Lembke W; McBlane F; Kamerud J; DeWall S; Tarcsa E; Fang X; Hofer L; Kavita U; Upreti VV; Gupta S; Loo L; Johnson AJ; Chandode RK; Stubenrauch KG; Vinzing M; Xia CQ; Jawa V
    Mol Ther Methods Clin Dev; 2022 Sep; 26():471-494. PubMed ID: 36092368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioanalysis of adeno-associated virus gene therapy therapeutics: regulatory expectations.
    Gorovits B; Marshall JC; Smith J; Whiteley LO; Neubert H
    Bioanalysis; 2019 Nov; 11(21):2011-2024. PubMed ID: 31648530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models.
    Chowdhury EA; Meno-Tetang G; Chang HY; Wu S; Huang HW; Jamier T; Chandran J; Shah DK
    Adv Drug Deliv Rev; 2021 Mar; 170():214-237. PubMed ID: 33486008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic stability of self-complementary adeno-associated virus 2 during early stages of transduction in mouse muscle in vivo.
    Ren C; Kumar S; Shaw DR; Ponnazhagan S
    Hum Gene Ther; 2005 Sep; 16(9):1047-57. PubMed ID: 16149903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy.
    Gorovits B; Azadeh M; Buchlis G; Fiscella M; Harrison T; Havert M; Janetzki S; Jawa V; Long B; Mahnke YD; McDermott A; Milton M; Nelson R; Vettermann C; Wu B
    AAPS J; 2023 Apr; 25(3):47. PubMed ID: 37101079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Adeno-associated Virus - A Safe and Promising Vehicle for Liverspecific Gene Therapy of Inherited and Non-inherited Disorders.
    Mak KY; Rajapaksha IG; Angus PW; Herath CB
    Curr Gene Ther; 2017; 17(1):4-16. PubMed ID: 28292253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays.
    Gorovits B; Fiscella M; Havert M; Koren E; Long B; Milton M; Purushothama S
    AAPS J; 2020 Jan; 22(2):24. PubMed ID: 31907680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioanalytical Assay Strategies and Considerations for Measuring Cellular Kinetics.
    Hays A; Durham J; Gullick B; Rudemiller N; Schneider T
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herpes simplex virus type 1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19.
    Heister T; Heid I; Ackermann M; Fraefel C
    J Virol; 2002 Jul; 76(14):7163-73. PubMed ID: 12072516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays.
    Gorovits B; Azadeh M; Buchlis G; Harrison T; Havert M; Jawa V; Long B; McNally J; Milton M; Nelson R; O'Dell M; Richards K; Vettermann C; Wu B
    AAPS J; 2021 Sep; 23(6):108. PubMed ID: 34529177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ring finger protein 121 is a potent regulator of adeno-associated viral genome transcription.
    Madigan VJ; Yuziuk JA; Chiarella AM; Tyson TO; Meganck RM; Elmore ZC; Tse LV; Hathaway NA; Asokan A
    PLoS Pathog; 2019 Aug; 15(8):e1007988. PubMed ID: 31386698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vivo Potency Assay for Adeno-Associated Virus-Based Gene Therapy Vectors Using AAVrh.10 as an Example.
    De BP; Chen A; Salami CO; Van de Graaf B; Rosenberg JB; Pagovich OE; Sondhi D; Crystal RG; Kaminsky SM
    Hum Gene Ther Methods; 2018 Jun; 29(3):146-155. PubMed ID: 29706115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of Size Exclusion Chromatography with Multiangle Light Scattering in the Analytical Development of a Preclinical Stage Gene Therapy Program.
    Troxell B; Tsai IW; Shah K; Knuckles CI; Shelton S; Lindsey K; Cardenas SMB; Roberts T
    Hum Gene Ther; 2023 Apr; 34(7-8):325-338. PubMed ID: 36927085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution of Adeno-Associated Virus Gene Therapy Following Cerebrospinal Fluid-Directed Administration.
    Chen X; Lim DA; Lawlor MW; Dimmock D; Vite CH; Lester T; Tavakkoli F; Sadhu C; Prasad S; Gray SJ
    Hum Gene Ther; 2023 Feb; 34(3-4):94-111. PubMed ID: 36606687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Perspective of DMPK on Recombinant Adeno-Associated Virus-Based Gene Therapy: Past Learning, Current Support, and Future Contribution.
    Chen N; Sun K; Chemuturi NV; Cho H; Xia CQ
    AAPS J; 2022 Jan; 24(1):31. PubMed ID: 35102450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
    Janelidze S; Nordström U; Kügler S; Brundin P
    J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.